OMOzgul Muneyyirci-Delale

Ozgul Muneyyirci-Delale

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ozgul Muneyyirci-Delale has a total of 78 co-authors. Here are the top co-authors by number of shared publications:

  • Ghadir Salame

    Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, New York, NY, USA

    3 shared publications
  • Ovadia Abulafia

    Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology; State University of New York, Downstate Medical Center; Brooklyn New York USA

    3 shared publications
  • Vijaya L Nacharaju

    3 shared publications
  • Vijaya L. Nacharaju

    Department of Obstetrics and Gynecology, SUNY Downstate Medical Center Brooklyn, NYUSA

    3 shared publications
  • Ashadeep Chandrareddy

    Departments of Obstetrics and Gynecology, SUNY Downstate Medical Center

    2 shared publications
  • Cassandra Charles

    Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, New York, NY, USA

    2 shared publications

Latest Publications

  • Open Access

    The Hypothalamus–Pituitary–Testicular Axis in a Healthy Aging Male

    by Joseph Goldblatt, Mudar Dalloul, Ozgul Muneyyirci-Delale

    The exact points of weakness along the aging hypothalamus–pituitary–testicular (HPT) axis remain undetermined. In this review, the HPT axis in healthy older males will be analyzed and compared to that in younger males. A systematic review of published literature related to “aging males” and the “hypothalamus–pituitary–testicular axis” was conducted using the PubMed, Web of Science, Google Scholar, and Embase online databases for articles published between January 1, 2003, and December 31, 2023. Gonadotropin-releasing hormone (GnRH) exhibits increased potency and a lower maximal effect on luteinizing hormone (LH) secretion with age. Serum LH, follicle-stimulating hormone (FSH), sex hormone-binding globulin (SHBG), and estradiol levels increase with age while the serum LH and testosterone (T) coordination desynchronize. Serum total testosterone (TT) levels decrease, and serum free testesterone(FT) and serum bioactive testesterone(FT) levels decrease even more. Indicators of Leydig and Sertoli cell function respectively, insulin-like 3 peptide decreased, and inhibin-B remained stable. Aging hypogonadism is a primary hypogonadism because serum gonadotropin levels increase as serum T levels decrease. However, there is also evidence that GnRH and LH stimulation decrease with age. A loss of Leydig cell function and a decrease in Sertoli cell count is observed via serum indi cators. Additionally, SHBG is implicated in the difference between serum TT and serum FT and BT. Due to the numerous influences on aging hypogonadism in men without comorbid endocrine disorders, it may be more accurate as global hypogonadism. Further study is needed for the various locations of desynchrony, hopefully leading to treatment and prevention options. Cite this article as: Goldblatt J, Dalloul M, Muneyyirci-Delale O. The hypothalamus pituitary–testicular axis in a healthy aging male. Endocrinol Res Pract. 2025;29(3):261-266.

  • Open Access

    Unraveling the impact of adenomyosis on obstetrical outcomes: a comprehensive review

    by Ranjitha Vasa, Ozgul Muneyyirci-Delale

    Objective: Adenomyosis’ impact on obstetrical outcomes is investigated with detailed discussion of plausible pathogenesis. Discussion of management strategies to improve outcomes included. Methods of study: Terms utilized include ‘adenomyosis’, ‘fertility’, ‘ pregnancy’, ‘obstetrical outcomes’, ‘preeclampsia, ‘fetal growth restriction’, ‘preterm labor’, ‘preterm prelabor rupture of membranes, ‘in vitro fertilization, ‘prelabor rupture of membranes’, ‘ultrasound’, ‘small for gestational age’, ‘cesarean section’ Inclusion criteria are English, between January 1990-January 2023, randomized controlled trials, case controls, cohorts, case series, case reports, systematic reviews, and meta-analyses. Exclusion criteria are studies/articles completed prior to 1990, non-relevant, and non-English. Results: Limited literature exists evaluating the relationship between adenomyosis impact on obstetrical outcomes. However, amongst available literature there exists statistically significant relationship between adenomyosis and adverse obstetrical, neonatal outcomes such as: ectopic pregnancy, placental abruption, pre-eclampsia (PEC), gestational diabetes (GDM), low birth weight (LBW), intra-uterine growth restriction (IUGR), and preterm prelabor rupture of membranes (PPROM). Proposed physiologic mechanisms include disordered anatomic, functional, and immunological environment in the uterus. Proposed management strategies to improve obstetrical outcomes include removal of focal adenomyotic lesions and pre-treatment with GnRH agonists before conception. Conclusion: Adenomyosis has a multifactorial impact on obstetrical outcomes; treatment modalities do exist to improve the chances of conception and retaining a pregnancy. However, more research is required to not only further substantiate treatment modalities relationship to improve pregnancy; but also to clarify adenomyosis impact on infertility

  • Open Access

    Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis

    by Ozgul Muneyyirci-Delale, David F. Archer, Charlotte D. Owens, Kurt T. Barnhart, Linda D. Bradley, Eve Feinberg, Veronica Gillispie, Sandra Hurtado, Jin Hee Kim, Alice Wang, et al.


  • Open Access

    Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids

    by Ayman Al-Hendy, Linda Bradley, Charlotte D. Owens, Hui Wang, Kurt T. Barnhart, Eve Feinberg, William D. Schlaff, Elizabeth E. Puscheck, Alice Wang, Veronica Gillispie, et al.


  • Elagolix for Fibroid-Associated Heavy Menstrual Bleeding

    by William D Schlaff, Charlotte D Owens, Ozgul Muneyyirci-Delale

    To the Editor: Schlaff et al. (Jan. 23 issue)1 discuss options for the management of uterine fibroids, mentioning a variety of interventional therapies and stating that data from randomized, controlled trials show that the effectiveness of these therapies is limited. We consider this statement to be misleading. On the contrary, since the publication of the 2008 practice guidelines from the American College of Obstetricians and Gynecologists, uterine-artery embolization has been recognized as one of three surgical options with level A evidence supporting its safety and effectiveness.2-4 All patients should be counseled about this surgical alternative during the process of informed . . .


  • Open Access

    Stress-Induced Hyperprolactinemia: Pathophysiology and Clinical Approach

    by Samara Levine, Ozgul Muneyyirci-Delale

    While prolactin is most well known for its role in lactation and suppression of reproduction, its physiological functions are quite diverse. There are many etiologies of hyperprolactinemia, including physiologic as well as pathologic causes. Physiologic causes include pregnancy, lactation, sleep-associated, nipple stimulation and sexual orgasm, chest wall stimulation, or trauma. Stress is also an important physiologic cause of hyperprolactinemia, and its clinical significance is still being explored. This review will provide an overview of prolactin physiology, the role of stress in prolactin secretion, as well as the general clinical approach to hyperprolactinemia.


  • Open Access

    Vascular compliance in women with polycystic ovary syndrome treated with spironolactone

    by Ozgul Muneyyirci‐Delale, Sherilyne Co, Nathaniel Winer

    Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age in the United States and has been associated with several diseases including cardiovascular disease, obesity, and glucose intolerance. In this study, systolic blood pressure, diastolic blood pressure, pulse pressure (vascular compliance), large artery elasticity, systemic vascular resistance (SVR), total vascular impedance (TVI), and body mass index (BMI) were measured before and after treatment with spironolactone in 10 women with PCOS. Systolic BP, diastolic BP, and BMI were similar prior to treatment and after treatment. Pulse pressure decreased slightly post‐treatment compared to pretreatment but not to significance (P = 0.07). The results show that after treatment with spironolactone, there was a statistically significant increase in large artery elasticity (P = 0.047), while there was a statistically significant decrease in SVR and TVI (P = 0.0005 and P = 0.03). This study indicates that treatment with spironolactone improves large artery elasticity and reduces systemic vascular resistance without any change in small artery elasticity.


  • Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone

    by Ozgul Muneyyirci-Delale, Julie Kaplan, Ibrahim Joulak, Lianfu Yang, Hans Von Gizycki, Vijaya L. Nacharaju

    To assess the effect of glucophage, magnesium oxide and spironolactone in altering free fatty acids (FFAs), 36 PCOS women were randomly divided into three groups. Group 1 (n = 14) was treated with 500 mg glucophage po bid, group 2 (n = 10) was treated with 400 mg magnesium oxide po bid and group 3 (n = 12) was treated with 50 mg spironolactone po bid for 12 weeks. A glucose tolerance test with 75 g glucose load was performed before and after treatment, collecting blood at 0, 1 and 2 h for insulin, glucose, FFA and aldosterone. Amount of FFA before and after treatment were compared by repeated measure ANOVA and represented as area under the curve. FFA levels before treatment were 0.83 ± 0.23, 0.77 ± 0.15 and 0.85 ± 0.28 and after treatment were 0.77 ± 0.48, 0.71 ± 0.18 and 0.66 ± 0.25 for glucophage, magnesium oxide and spironolactone-treated patients, respectively. The FFA levels were unchanged in the groups treated with glucophage and magnesium oxide but were significantly (p < 0.03) decreased in the group treated with spironolactone. Since FFAs are known to be involved in the development of insulin resistance, these results suggest that spironolactone may be useful for lowering insulin resistance in PCOS patients.


  • Open Access

    Medical management of recurrent endometrioma with long-term norethindrone acetate

    by Ozgul Muneyyirci-Delale, Jenny Anopa, Cassandra Charles, Deepali Mathur, Rudolph Parris, Jed B Cutler, Ghadir Salame, Ovadia Abulafia

    Purpose: Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and regression of recurrent endometrioma. Patients and methods: Retrospective chart review at SUNY Downstate Medical Center of patients with a history of surgical excision of endometrioma (with histological confirmation) and recurrent endometrioma (demonstrated by strict sonographic criterion of endometrioma) who were willing to undergo follow-up. Patients were prescribed norethindrone acetate to be taken daily with follow-up sonograms until cysts regressed. Statistical analysis included Student's t-test and a simple linear regression model to assess cyst regression over time during treatment. Results: Degree of pain was significantly lower on treatment when compared to baseline (P < 0.00001). Cyst size was significantly smaller in as little as 3 months (P < 0.0001). Average rate of regression with continuous treatment was 0.025 ± 0.015 cm/day. Total mean ± standard deviation regression time is 10.28 ± 8.25 months. Conclusion: Norethindrone acetate was effective in eradicating symptoms and producing complete regression of recurrent endometriomas. It should be considered for patients who are likely to adhere to a prolonged treatment regimen and comply with recommendations for surveillance with serial sonograms.


  • Determination of Urinary Cortisol Metabolites in Spot Urine of Patients with Uterine Cancer Utilizing Segmental GC/MS/MS

    by Vijaya L Nacharaju, Yi-Chun Lee, Ghadir Salame, Tana Shah, Erin Stevens, Katherine Economos, Constantine Gorelick, Ozgul Muneyyirci-Delale, Ovadia Abulafia

    Urinary cortisol metabolites were studied intensively by several investigators using GC/MS method of analysis. In general 24-hour urine collection is used for steroid analysis. Measuring cortisol metabolites, especially urinary free cortisol in spot urine is difficult due to dilution effect. We developed a method using segmental GC/MS/MS analysis to achieve this goal. We previously described 11β-HSD enzyme activity in endometrial cancer (Manolis et al, Gynecol Obstet Invest, 2006). The ability to analyze cortisol metabolites in spot urine may provide valuable metabolic information in this disease. Spot urines samples from 14 patients with endometrial cancer were analyzed. Steroid conjugates were extracted from 5 ml of spot urine using C-18 columns and subjected to hydrolysis by glucoronidase enzyme for 48 hours at 37° C. Steroids were re-extracted after hydrolysis by C-18 columns. The free steroids were derivatized to Methoxime-trimethylsilyl derivatives and one µl of this mixture was injected into varian 2200 GC/MS instrument using auto-injector. Based on EI/MS mass spectra, conditions were determined to achieve optimal sensitivity by MS/MS isolation and collision induced dissociation of the molecular ion. The steroid metabolites of interest were determined in two consecutive injections. First injection was made to determine internal standard diethyl stilbestrol (DES) in a segment 4-15 minutes, THF and allo-THF in a segment 15-18 minutes and free cortisol in a segment between 18 to 25.5 minutes. The second consecutive injection was made to determine DES as above and THE in a segment 15-18 and free cortisone in a segment 18-25.5. Appropriate excitation storage levels were chosen for each segment based on parent molecular weight. The separation of interested steroids was achieved by using 2° C/min temperature increments between 250° C and 290° C. A method using segmental GC/MS/MS was developed to analyze cortisol metabolites from spot urine. We were able to measure free cortisol in all 14 specimens. The two consecutive injections facilitate determination of THE and THF levels without interference, as these compounds elute closely. This ratio of (THF + allo-THF)/THE in spot urine specimens of patients with endometrial carcinoma was 1.11± 1.21 (mean ± SD). Our data suggest that the ability to determine free cortisol levels in spot urine may assist in understanding cortisol metabolism in patients with gynecologic malignancies. Nothing to Disclose: VLN, Y-CL, GS, TS, ES, KE, CG, OM-D, OA